These findings suggest that poor outcomes associated with GATA6hi and KRT17hi expression in post-CTX samples involve a higher relative enrichment of GATA6+KRT17+ and GATA6–KRT17+ cells and near loss of GATA6+KRT17– cells. The gene discussed is KRT17; the disease is cerebrotendinous xanthomatosis.